Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLENA PHARMACEUTICALS, INC.

(ALNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Allena Pharmaceuticals : to Participate in H.C. Wainwright's 23rd Annual Global Investment Conference

09/09/2021 | 08:31am EDT

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will virtually participate in H.C. Wainwright’s 23rd Annual Global Investment Conference, being held September 13th – 15th, 2021.

Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will virtually participate in a fireside chat at the conference. The pre-recorded discussion will be available on demand beginning 7:00 a.m. ET on September 13th. A recording can also be accessed for 90 days at the link below or via the Allena Pharmaceuticals website within the Investors/Events and Presentations section.

Please see details for the session below:

Date:7:00 a.m. ET
Time:Monday, September 13th, 2021
Webcast:https://journey.ct.events/view/f1d0178c-8b66-4f9b-bbb4-f26ad0dc2801

Management will also be available for 1x1 meetings. If you would like to request a meeting, please email meetings@hcwco.com.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program recently initiated.

Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com 


Primary Logo

Source: Allena Pharmaceuticals, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about ALLENA PHARMACEUTICALS, INC.
09/29ALLENA PHARMACEUTICALS : Doses First Patient in Mid-Stage Trial of Potential Gout Treatmen..
MT
09/29ALLENA PHARMACEUTICALS : Commences Dosing of Gout Patients in Second Phase 2a Trial of ALL..
PU
09/29ALLENA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/29ALLENA PHARMACEUTICALS : Commences Dosing of Gout Patients in Second Phase 2a Trial of ALL..
AQ
09/29Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of AL..
CI
09/14ALLENA PHARMACEUTICALS : Corporate Presentation September 2021
PU
09/10ALLENA PHARMACEUTICALS : to Participate in H.C. Wainwright's 23rd Annual Global Investment..
AQ
09/09ALLENA PHARMACEUTICALS : to Participate in H.C. Wainwright's 23rd Annual Global Investment..
AQ
08/27ALLENA PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listi..
AQ
08/27ALLENA PHARMACEUTICALS : Delisting/Transfer of Listing (Form 8-K)
PU
More news
Analyst Recommendations on ALLENA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,7 M - -
Net cash 2021 18,6 M - -
P/E ratio 2021 -1,03x
Yield 2021 -
Capitalization 66,5 M 66,5 M -
EV / Sales 2021 -
EV / Sales 2022 47,9x
Nbr of Employees 47
Free-Float 98,5%
Chart ALLENA PHARMACEUTICALS, INC.
Duration : Period :
Allena Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLENA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,83 $
Average target price 6,13 $
Spread / Average Target 638%
EPS Revisions
Managers and Directors
Louis Brenner President, Chief Executive Officer & Director
Richard D. Katz Chief Financial & Accounting Officer
Alexey L. Margolin Chairman
Hugh Wight Senior Vice President-Technical Operations
David J. Clark Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLENA PHARMACEUTICALS, INC.-33.59%68
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.20.76%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753